^
    Back
    Association details:
    Biomarker:EML4-ALK G1269A
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    J Thorac Oncol
    Title:

    Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer

    Excerpt:
    ALK Mutations Confer Resistance to Crizotinib.
    DOI:
    https://doi.org/10.1097/JTO.0b013e318283dcc0
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Cancer Discov
    Title:

    The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer

    Excerpt:
    In Ba/F3 models, ceritinib was highly active against L1196M, G1269A, S1206Y...The initial interrogation of ceritinib resistant patient biopsies supports the notion that ceritinib is able to effectively suppress many crizotinib-resistance mutations…This suggests that predominant clones with the S1206Y and G1269A mutations were suppressed by ceritinib...
    DOI:
    10.1158/2159-8290.CD-13-0846